Press release
Andrew Hopkins, Chief Executive at Exscientia to discuss the role of Artificial Intelligence in small molecule drug discovery
SMi reports: Andrew Hopkins, Chief Executive at Exscientia to discuss the role of Artificial Intelligence in small molecule drug discovery at SMi’s Drug Discovery conference in March 2018The world’s leading drug companies are turning to artificial intelligence to improve the hit-and-miss business of finding new medicines, with GlaxoSmithKline unveiling a new $43 million deal in the field on Sunday.“Many large pharma companies are starting to realize the potential of this approach and how it can help improve efficiencies,” said Andrew Hopkins, Chief Executive of privately owned Exscientia.Hopkins said Exscientia’s AI system could deliver drug candidates in roughly one-quarter of the time and at one-quarter of the cost of traditional approaches [Source: Reuters]
Hear from Andrew Hopkins, Chief Executive Officer of Exscientia at Drug Discovery conference in London next March where he will discuss "Transforming Small Molecule Drug Discovery using Artificial Intelligence". His presentation will cover the following:
• Exscientia’s automated design process mimics human creativity by designing molecules which integrate the wealth of available data
• Discover how Exscientia’s AI is delivering pre-clinical candidates with exception productivity
• Learn how artificial intelligence and human expertise can be best combined to re-design the drug discovery process
• The potential of AI to increase the capital efficacy of R&D
Andrew Hopkins, Exscientia will be joined by Mark Davies, Vice President, Biomedical Informatics, Benevolent AI, Claus Bendtsen, Executive Director & Head of Quantitative Biology, AstraZeneca, Gisbert Schneider, Professor, Chair for Computer-Assisted Drug Design, ETH Zurich. These expert speakers will all presebt on the new role of artificial intelligence in drug discovery. Visit our website and download the brochure for the full agenda.
Alongside the two-day conference, there will be two pre-conference workshops taking place on Tuesday 20th March 2018. The morning session will be led by Nicolas Clare, Technical Project Leader at Axol Bioscience. He will discuss Induced Pluripotent Stem Cell Derived Models and their use in Drug Discovery. The workshop is aimed at those who would like to understand the revolutionary biological technique of creating induced pluripotent stem cells (Ipsc) from any source material, differentiating them into different cell lineages and their use in drug discovery, either as healthy controls or disease models.
The afternoon workshop will be led by Emanuela Cuomo, Associate Principal Scientist at AstraZeneca who will provide an overview of CRISPR/Cas technologies and how they are applied to drug development. Specific examples will illustrate how genome editing is used in AstraZeneca pipeline to improve target identification and validation; also how it can be used to predict drug resistance and direct drug optimisation.
For more details about the conference and registration information, visit www.drug-discovery.co.uk/openpr
Drug Discovery
21st – 22nd March 2018
Copthorne Tara Hotel, London, UK
---end ---
Contact Information:
For sponsorship and exhibition queries please contact Alia Malick at amalick@smi-online.co.uk. For delegate queries please contact Kieran Ronaldson at kronaldson@smi-online.co.uk. For media queries please contact Natasha Boumediene at nboumediene@smi-online.co.uk.
About SMi Group:
Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world’s most forward thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at http://www.smi-online.co.uk
1 WESTMINSTER BRIDGE ROAD
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Andrew Hopkins, Chief Executive at Exscientia to discuss the role of Artificial Intelligence in small molecule drug discovery here
News-ID: 839280 • Views: …
More Releases from SMi Group

Exclusive Speaker Interview with AOBiome ahead of the 22nd Pain Therapeutics Con …
SMi Reports: Exclusive speaker interview with Todd Krueger at AOBiome released for the Pain Therapeutics Conference
The pain therapeutics industry has grown at an exponential rate in recent years. The 22nd Annual Pain Therapeutics conference will cover the leading advances in pain therapeutics, exploring late development clinical trials, novel treatments for chronic conditions, technology collaboration treatments, using VR and Medical Devices that carry out non-invasive nerve stimulation.
Industry leaders will uncover the…

Exclusive Speaker Interview with Ester Lovsin Barle ahead of the 6th Annual High …
Now in its 6th year, the Highly Potent Active Pharmaceutical Ingredients conference offers you peer-to-peer networking with industry experts including heads and directors of EHS, Occupational Hygiene, Quality Assurance and more. Taking place on 9th and 10th May in London, UK.
With a key focus on expanding your community and exploring the latest developments in the industry at this two-day event, including key regulatory updates, and leading case studies from leading…

FDA Keynote Speaker at SMi's 5th Annual Pharmaceutical Microbiology East Coast C …
SMi Group Reports: Keynote FDA speaker Dr. John Arigo, to present at the 4th Annual Pharmaceutical Microbiology East Coast, taking place in just 3 weeks' time on April 27th and 28th, 2022.
With just three weeks remaining until the highly anticipated conference, SMi Group are delighted to announce a key FDA Speaker joining the 5th Annual Pharmaceutical Microbiology East Coast Conference. This event will take place on April 27th and…
Group Captain (ret'd) Robert Daisley invites you to attend Air Mission Planning …
SMi Group reports: Chairman Group Captain (ret'd) Robert Daisley of the Air Mission Planning and Support Conference cordially invites experts to join the conference in London, UK in one week.
With only one week remaining, SMi Group is delighted to publish an invitation letter for SMi's 13th Annual Air Mission Planning & Support Conference, taking place on the 6th and 7th April 2022 in London, UK from the conference chairman.
The…
More Releases for Exscientia
AI for Drug Discovery and Development Market Is Booming So Rapidly | Major Giant …
According to HTF Market Intelligence, the Global AI for Drug Discovery and Development market to witness a CAGR of 29.6% during the forecast period (2025-2030). The Latest Released AI for Drug Discovery and Development Market Research assesses the future growth potential of the AI for Drug Discovery and Development market and provides information and useful statistics on market structure and size.
This report aims to provide market intelligence and strategic insights…
Immuno-Oncology Clinical Trials Market erated Opportunities, Future Scope By 203 …
Overview
The "Immuno-Oncology Clinical Trials Market 2025 Forecast to 2032" research provides accurate economic, global, and country-level predictions and analyses. It provides a comprehensive perspective of the competitive market as well as an in-depth supply chain analysis to assist businesses in identifying major changes in industry practices. The market report also examines the current state of the Immuno-Oncology Clinical Trials industry, as well as predicted future growth, technological advancements, investment prospects,…
AI in Pharmaceutical Market May Set New Growth Story | IBM Watson Health, Benevo …
HTF MI just released the Global AI in Pharmaceutical Market Study, a comprehensive analysis of the market that spans more than 143+ pages and describes the product and industry scope as well as the market prognosis and status for 2025-2032. The marketization process is being accelerated by the market study's segmentation by important regions. The market is currently expanding its reach.
Major Giants in AI in Pharmaceutical Market are:
IBM Watson Health,…
Deadline on June 25th coming up in Lawsuit for Investors in Exscientia plc (NASD …
A deadline is coming up on June 25, 2024 in the lawsuit filed for certain investors of Exscientia plc (NASDAQ: EXAI) over alleged securities laws violations by Exscientia plc.
Investors who purchased shares of Exscientia plc (NASDAQ: EXAI) have certain options and there are strict and short deadlines running. Deadline: June 25, 2024. NASDAQ: EXAI stockholders should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
According to the…
Investigation announced for Investors in Exscientia plc (NASDAQ: EXAI) over poss …
Exscientia plc is under investigation over potential securities laws violations in connection with certain financial statements.
Investors who purchased shares of Exscientia plc (NASDAQ: EXAI), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm focuses on possible claims on behalf of purchasers of the securities of Exscientia plc (NASDAQ: EXAI) concerning whether a series of statements by Exscientia…
Brain Computer Interface Market Market Growing Trends and Demands Analysis Forec …
Infinity Business Insights has newly added the report Brain Computer Interface Market 2024-2030 to acquire a stronger and more effective company view. The Brain-Computer Interface market holds immense potential as advancements in neuroscience and technology enable direct communication between the brain and external devices. With applications ranging from healthcare and rehabilitation to gaming and assistive technologies, BCI systems offer innovative solutions for enhancing human-machine interaction and augmenting human capabilities. Factors…